S&P Futures
3,852.25 +4.00 (+0.10%) Dow Futures
31,042.00 +29.00 (+0.09%) Nasdaq Futures
11,897.75 +17.50 (+0.15%) Russell 2000 Futures
1,730.90 +2.30 (+0.13%) Crude Oil
98.29 -0.24 (-0.24%) Gold
1,738.50 +2.00 (+0.12%)
Co-Diagnostics, Inc. (CODX)
After hours:
Chart Events
Performance Outlook
| Previous Close | 6.12 |
| Open | 6.12 |
| Bid | 5.86 x 1100 |
| Ask | 6.20 x 1800 |
| Day's Range | 5.83 - 6.23 |
| 52 Week Range | 3.66 - 11.82 |
| Volume | |
| Avg. Volume | 363,465 |
| Market Cap | 172.919M |
| Beta (5Y Monthly) | -1.54 |
| PE Ratio (TTM) | 4.16 |
| EPS (TTM) | 1.42 |
| Earnings Date | Nov 15, 2021 - Nov 19, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 19.33 |
- Motley Fool
Why Co-Diagnostics Is Running Higher Today
Shares of Co-Diagnostics (NASDAQ: CODX) were running 4.6% higher Tuesday morning as of 10:30 a.m. ET on no company-specific news, though it may be getting a boost from an update from the World Health Organization (WHO). The World Health Organization reported this morning there are 5,322 laboratory-confirmed cases of monkeypox. Co-Diagnostics CEO Dwight Egan has said the healthcare company was founded to make low-cost, high-quality tests available wherever they're needed, and it looks "forward to eventually making this test available in affected regions as needed to help slow the spread of the virus through early and accurate detection."
- PR Newswire
Co-Diagnostics, Inc. to Present at 29th International Biodetection Technologies Virtual Conference
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx,"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be presenting this week at the 29th International Biodetection Technologies Conference, held virtually June 28-29, 2022.
- Zacks
CoDiagnostics, Inc. (CODX) Surges 5.6%: Is This an Indication of Further Gains?
CoDiagnostics, Inc. (CODX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
